Maze Therapeutics Inc (MAZE) Quality Analysis

MAZE GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

MAZE Profitability

Profitability trend analysis coming soon

MAZE Growth

Growth trend analysis coming soon

MAZE Financial Health

Financial health indicators coming soon

MAZE Quality & Fundamental Analysis

Maze Therapeutics Inc (MAZE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Maze Therapeutics Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Maze Therapeutics Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -612.71% and a return on equity (ROE) of -34.52%. Return on assets (ROA) stands at -30.86%.

The debt-to-equity ratio is 0.07, with a current ratio of 15.50.

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Maze Therapeutics Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.